- Home
- PLX vs CRBP Comparison
PLX vs CRBP Comparison
Compare PLX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | CRBP |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 190.3M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLX | CRBP |
|---|---|---|
| Price | $2.76 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.03 |
| AVG Volume (30 Days) | 767.5K | ★ 1.1M |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | $4,822,272.00 |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $10.30 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.60 | $5.11 |
| 52 Week High | $3.19 | $20.56 |
Technical Indicators
Market Signals| Indicator | PLX | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 20.97 |
| Support Level | $2.59 | N/A |
| Resistance Level | $2.85 | $9.66 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 69.22 | 0.36 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.